Pharmacovigilance Market - Size, Share & Trends Report, 2032

Pharmacovigilance Market - By Type (Software, Service {By Process, By Activity [Spontaneous Reporting, Intensified Adverse Drug Reaction Reporting, Cohort Event Monitoring]}), By Clinical Trial Phase, Service Provider, By End-use, & Forecast, 2023 – 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Industry coverage

1.2&nbsp;&nbsp;&nbsp; Market scope and definitions

1.3&nbsp;&nbsp;&nbsp; Base estimates and working

1.4&nbsp;&nbsp;&nbsp; Forecast parameters

1.5&nbsp;&nbsp;&nbsp; COVID-19 impact analysis at global level

1.6&nbsp;&nbsp;&nbsp; Data validation

1.7&nbsp;&nbsp;&nbsp; Data sources

1.7.1&nbsp;&nbsp;&nbsp; Primary

1.7.2&nbsp;&nbsp;&nbsp; Secondary

1.7.2.1&nbsp;&nbsp;&nbsp; Paid sources

1.7.2.2&nbsp;&nbsp;&nbsp; Unpaid sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Pharmacovigilance industry 3600 synopsis, 2018 - 2032

2.1.1&nbsp;&nbsp;&nbsp; Business trends

2.1.2&nbsp;&nbsp;&nbsp; Type trends

2.1.3&nbsp;&nbsp;&nbsp; Clinical trial phase trends

2.1.4&nbsp;&nbsp;&nbsp; Service provider trends

2.1.5&nbsp;&nbsp;&nbsp; End-user trends

2.1.6&nbsp;&nbsp;&nbsp; Regional trends

Chapter 3&nbsp;&nbsp;&nbsp;Pharmacovigilance Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry segmentation

3.2&nbsp;&nbsp;&nbsp; Industry landscape, 2018 &ndash; 2032

3.3&nbsp;&nbsp;&nbsp; Industry impact forces

3.3.1&nbsp;&nbsp;&nbsp; Growth drivers

3.3.1.1&nbsp;&nbsp;&nbsp; Increasing need of new drugs

3.3.1.2&nbsp;&nbsp;&nbsp; Rising investment on R&amp;D by pharmaceutical companies

3.3.1.3&nbsp;&nbsp;&nbsp; Rise in incidences of adverse drug reactions (ADR) and drug toxicity

3.3.1.4&nbsp;&nbsp;&nbsp; Increasing focus on personalized medicine

3.3.1.5&nbsp;&nbsp;&nbsp; Increasing trend of outsourcing pharmacovigilance services

3.3.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.3.2.1&nbsp;&nbsp;&nbsp; High risk associated with data security

3.3.2.2&nbsp;&nbsp;&nbsp; Lack of skilled healthcare professionals

3.4&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4.1&nbsp;&nbsp;&nbsp; By type

3.4.2&nbsp;&nbsp;&nbsp; By clinical trial phase

3.4.3&nbsp;&nbsp;&nbsp; By service provider

3.4.4&nbsp;&nbsp;&nbsp; By end-use

3.5&nbsp;&nbsp;&nbsp; COVID-19 impact analysis

3.6&nbsp;&nbsp;&nbsp; Regulatory landscape

3.6.1&nbsp;&nbsp;&nbsp; U.S.

3.6.2&nbsp;&nbsp;&nbsp; Europe

3.7&nbsp;&nbsp;&nbsp; Technology landscape

3.7.1&nbsp;&nbsp;&nbsp; Artificial intelligence (AI) in pharmacovigilance

3.7.2&nbsp;&nbsp;&nbsp; Natural language processing (NLP) in pharmacovigilance

3.8&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.9&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2022

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis, 2022

4.3&nbsp;&nbsp;&nbsp; Company positioning matrix

4.4&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.5&nbsp;&nbsp;&nbsp; Strategic outlook matrix

4.6&nbsp;&nbsp;&nbsp; Company market share analysis, 2022

4.7&nbsp;&nbsp;&nbsp; Strategy dashboard, 2022

Chapter 5&nbsp;&nbsp;&nbsp;Pharmacovigilance Market, By Type

5.1&nbsp;&nbsp;&nbsp; Key type trends

5.2&nbsp;&nbsp;&nbsp; Software

5.2.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, 2018 - 2032 (USD Million)

5.3&nbsp;&nbsp;&nbsp; Service

5.3.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, 2018 - 2032 (USD Million)

5.3.2&nbsp;&nbsp;&nbsp; By Process

5.3.2.1&nbsp;&nbsp;&nbsp; Core services

5.3.2.1.1&nbsp;&nbsp;&nbsp;Market estimates and forecast, 2018 - 2032 (USD Million)

5.3.2.2&nbsp;&nbsp;&nbsp; Consulting services

5.3.2.2.1&nbsp;&nbsp;&nbsp;Market estimates and forecast, 2018 - 2032 (USD Million)

5.3.3&nbsp;&nbsp;&nbsp; By Activity

5.3.3.1&nbsp;&nbsp;&nbsp; Spontaneous Reporting

5.3.3.1.1&nbsp;&nbsp;&nbsp;Market estimates and forecast, 2018 - 2032 (USD Million)

5.3.3.2&nbsp;&nbsp;&nbsp; Intensified Adverse Drug Reaction (ADR) Reporting

5.3.3.2.1&nbsp;&nbsp;&nbsp;Market estimates and forecast, 2018 - 2032 (USD Million)

5.3.3.3&nbsp;&nbsp;&nbsp; Cohort Event Monitoring

5.3.3.3.1&nbsp;&nbsp;&nbsp;Market estimates and forecast, 2018 - 2032 (USD Million)

5.3.3.4&nbsp;&nbsp;&nbsp; EHR Mining

5.3.3.4.1&nbsp;&nbsp;&nbsp;Market estimates and forecast, 2018 - 2032 (USD Million)

5.3.3.5&nbsp;&nbsp;&nbsp; Others

5.3.3.5.1&nbsp;&nbsp;&nbsp;Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 6&nbsp;&nbsp;&nbsp;Pharmacovigilance Market, By Clinical Trial Phase

6.1&nbsp;&nbsp;&nbsp; Key clinical trial phase trends

6.2&nbsp;&nbsp;&nbsp; Pre-clinical

6.2.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, 2018 - 2032 (USD Million)

6.3&nbsp;&nbsp;&nbsp; Phase 1

6.3.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, 2018 - 2032 (USD Million)

6.4&nbsp;&nbsp;&nbsp; Phase 2

6.4.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, 2018 - 2032 (USD Million)

6.5&nbsp;&nbsp;&nbsp; Phase 3

6.5.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, 2018 - 2032 (USD Million)

6.6&nbsp;&nbsp;&nbsp; Phase 4

6.6.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 7&nbsp;&nbsp;&nbsp;Pharmacovigilance Market, By Service Provider

7.1&nbsp;&nbsp;&nbsp; Key service provider trends

7.2&nbsp;&nbsp;&nbsp; In-house

7.2.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, 2018 - 2032 (USD Million)

7.3&nbsp;&nbsp;&nbsp; Contract outsourcing

7.3.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 8&nbsp;&nbsp;&nbsp;Pharmacovigilance Market, By End-use

8.1&nbsp;&nbsp;&nbsp; Key end-use trends

8.2&nbsp;&nbsp;&nbsp; Pharmaceutical &amp; biotechnological companies

8.2.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, 2018 - 2032 (USD Million)

8.3&nbsp;&nbsp;&nbsp; Medical device companies

8.3.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, 2018 - 2032 (USD Million)

8.4&nbsp;&nbsp;&nbsp; Hospitals

8.4.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, 2018 - 2032 (USD Million)

8.5&nbsp;&nbsp;&nbsp; Others

8.5.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 9&nbsp;&nbsp;&nbsp;Pharmacovigilance Market, By Region

9.1&nbsp;&nbsp;&nbsp; Key regional trends

9.2&nbsp;&nbsp;&nbsp; North America

9.2.1&nbsp;&nbsp;&nbsp; U.S.

9.2.2&nbsp;&nbsp;&nbsp; Canada

9.3&nbsp;&nbsp;&nbsp; Europe

9.3.1&nbsp;&nbsp;&nbsp; Germany

9.3.2&nbsp;&nbsp;&nbsp; UK

9.3.3&nbsp;&nbsp;&nbsp; France

9.3.4&nbsp;&nbsp;&nbsp; Italy

9.3.5&nbsp;&nbsp;&nbsp; Spain

9.3.6&nbsp;&nbsp;&nbsp; Rest of Europe

9.4&nbsp;&nbsp;&nbsp; Asia Pacific

9.4.1&nbsp;&nbsp;&nbsp; China

9.4.2&nbsp;&nbsp;&nbsp; India

9.4.3&nbsp;&nbsp;&nbsp; Japan

9.4.4&nbsp;&nbsp;&nbsp; Australia

9.4.5&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

9.5&nbsp;&nbsp;&nbsp; Latin America

9.5.1&nbsp;&nbsp;&nbsp; Brazil

9.5.2&nbsp;&nbsp;&nbsp; Mexico

9.5.3&nbsp;&nbsp;&nbsp; Argentina

9.5.4&nbsp;&nbsp;&nbsp; Rest of Latin America

9.6&nbsp;&nbsp;&nbsp; Middle East &amp; Africa

9.6.1&nbsp;&nbsp;&nbsp; South Africa

9.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

9.6.3&nbsp;&nbsp;&nbsp; UAE

9.6.4&nbsp;&nbsp;&nbsp; Qatar

9.6.5&nbsp;&nbsp;&nbsp; Israel

9.6.6&nbsp;&nbsp;&nbsp; Rest of Middle East &amp; Africa

Chapter 10&nbsp;&nbsp;&nbsp;Company Profiles

10.1&nbsp;&nbsp;&nbsp; Accenture

10.2&nbsp;&nbsp;&nbsp; Cognizant

10.3&nbsp;&nbsp;&nbsp; Labcorp Drug Development

10.4&nbsp;&nbsp;&nbsp; IBM Corporation

10.5&nbsp;&nbsp;&nbsp; ArisGlobal

10.6&nbsp;&nbsp;&nbsp; ICON plc

10.7&nbsp;&nbsp;&nbsp; United BioSource LLC

10.8&nbsp;&nbsp;&nbsp; Pharmaceutical Development Group, Inc.

10.9&nbsp;&nbsp;&nbsp; Wipro Limited

10.10&nbsp;&nbsp;&nbsp; Allucent 
&nbsp;

Pharmacovigilance Market

Customize This Report

Industries

Information

Link

Global Headquarters